Terns Pharmaceuticals, Inc.
ternspharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 10-K, filed Mar 30, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Jun 5, 2026.
10-K for FY2025, filed Mar 30, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops oncology drug candidates, led by an oral chronic myeloid leukemia medicine for patients, alongside metabolic-disease programs it seeks to advance with partners.
10-K for FY2025, filed Mar 30, 2026
Who Were Their Customers?
Corporate collaborators may license intellectual property and fund research and development; future drug sales are planned through internal resources and third-party relationships.
10-K for FY2025, filed Mar 30, 2026The Company enters into corporate collaborations under which it may obtain upfront license fees, research and development funding, and…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
We intend to establish a targeted commercial infrastructure in key geographies at the appropriate time prior to regulatory approval of our…View ↗
How Were They Changing?
-
May 5, 2026
Merck completed its acquisition of Terns
Terns became a wholly owned Merck subsidiary after the merger.
Sources
8-K, filed May 5, 2026
The Offer and related withdrawal rights expired as scheduled at one minute following 11:59 p.m., Eastern time, on May 4, 2026 (such date…View ↗
Metabolic programs move toward partnering
The older report described active metabolic-disease development and obesity discovery; the latest report treats these programs as legacy efforts, seeks partners to advance some, and says it will no longer advance its oral obesity candidate.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 30, 2026Company OverviewView ↗
Our other clinical stage program is TERN-501, a THR-β agonist with high metabolic stability, enhanced liver distribution and greater…View ↗
We are also discovering and developing oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of obesity.…View ↗
Who Did They Compete With?
Competes with Ascentage Pharma Group, Innovent Biologics, Bristol Myers Squibb, Enliven Therapeutics, Jiangsu Hansoh Pharmaceutical Group, Novartis Pharmaceuticals, Pfizer, Shenzhen TargetRx, Sun Pharma Industries, Il-Yang Pharmaceutical, Takeda Pharmaceutical, and Incyte
10-K for FY2025, filed Mar 30, 2026We are aware of both pharmaceutical and biotechnology companies with development programs in CML. Companies that have recently participated…View ↗
Loading...
